Search details
1.
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody.
PLoS Pathog
; 20(4): e1011680, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38635853
2.
Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.
J Infect Dis
; 2024 May 08.
Article
in English
| MEDLINE | ID: mdl-38716969
3.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.
N Engl J Med
; 385(25): 2348-2360, 2021 12 16.
Article
in English
| MEDLINE | ID: mdl-34587382
4.
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
N Engl J Med
; 385(7): 595-608, 2021 08 12.
Article
in English
| MEDLINE | ID: mdl-34379922
5.
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
Ann Intern Med
; 176(3): 348-354, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36802755
6.
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults.
PLoS Genet
; 17(4): e1009464, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33901188
7.
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
Ann Intern Med
; 176(5): 658-666, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37068272
8.
ACTIV-2: A Platform Trial for the Evaluation of Novel Therapeutics for the Treatment of Early COVID-19 in Outpatients.
J Infect Dis
; 228(Suppl 2): S77-S82, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650231
9.
Pooling Different Placebos as a Control Group in a Randomized Platform Trial: Benefits and Challenges From Experience in the ACTIV-2 COVID-19 Trial.
J Infect Dis
; 228(Suppl 2): S92-S100, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650234
10.
Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.
J Infect Dis
; 228(Suppl 2): S83-S91, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650237
11.
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19.
J Infect Dis
; 228(2): 133-142, 2023 07 14.
Article
in English
| MEDLINE | ID: mdl-36661240
12.
Association Between Anterior Nasal and Plasma SARS-CoV-2 RNA Levels and Hospitalization or Death in Nonhospitalized Adults With Mild-to-Moderate COVID-19.
J Infect Dis
; 228(Suppl 2): S117-S125, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650230
13.
Variant-Specific Viral Kinetics in Acute COVID-19.
J Infect Dis
; 228(Suppl 2): S136-S143, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650233
14.
Immune Status and SARS-CoV-2 Viral Dynamics.
J Infect Dis
; 228(Suppl 2): S111-S116, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650232
15.
Long COVID After Bamlanivimab Treatment.
J Infect Dis
; 228(Suppl 2): S126-S135, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650236
16.
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical Trials.
J Infect Dis
; 228(Suppl 2): S101-S110, 2023 08 31.
Article
in English
| MEDLINE | ID: mdl-37650235
17.
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019.
Clin Infect Dis
; 76(4): 734-737, 2023 02 18.
Article
in English
| MEDLINE | ID: mdl-36210483
18.
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
Clin Infect Dis
; 77(7): 941-949, 2023 10 05.
Article
in English
| MEDLINE | ID: mdl-37279602
19.
Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus.
Clin Infect Dis
; 77(6): 866-874, 2023 09 18.
Article
in English
| MEDLINE | ID: mdl-37183889
20.
Adherence to Antiretrovirals and HIV Viral Suppression Under COVID-19 Pandemic Interruption - Findings from a Randomized Clinical Trial Using Ingestible Sensors to Monitor Adherence.
AIDS Behav
; 27(12): 4041-4051, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-37401993